State Street
MLYS icon

State Street’s Mineralys Therapeutics MLYS Stock Holding History

State Street’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112M Buy
4,141,636
+1,205,696
+41% +$33.1M ﹤0.01% 1421
2026
Q1 		$79.5M Sell
2,935,940
-249,059
-8% -$7.3M ﹤0.01% 1502
2025
Q4 		$116M Buy
3,184,999
+1,881,976
+144% +$75.5M ﹤0.01% 1272
2025
Q3 		$49.4M Sell
1,303,023
-140,536
-10% -$3.04M ﹤0.01% 1729
2025
Q2 		$19.5M Buy
1,443,559
+923,379
+178% +$13.4M ﹤0.01% 2199
2025
Q1 		$8.26M Buy
520,180
+15,647
+3% +$180K ﹤0.01% 2651
2024
Q4 		$6.21M Buy
504,533
+20,767
+4% +$272K ﹤0.01% 2870
2024
Q3 		$5.86M Buy
483,766
+18,627
+4% +$225K ﹤0.01% 2888
2024
Q2 		$5.44M Buy
465,139
+159,453
+52% +$2.01M ﹤0.01% 2891
2024
Q1 		$3.95M Buy
305,686
+23,602
+8% +$291K ﹤0.01% 3019
2023
Q4 		$2.43M Buy
282,084
+52,107
+23% +$409K ﹤0.01% 3251
2023
Q3 		$2.19M Buy
229,977
+18,780
+9% +$245K ﹤0.01% 3289
2023
Q2 		$3.6M Buy
211,197
+76,397
+57% +$1.14M ﹤0.01% 3159
2023
Q1 		$2.11M Buy
+134,800
New +$2.27M ﹤0.01% 3321

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street's MLYS Position: Q2 2026 in Review

State Street increased its Mineralys Therapeutics (MLYS) stake by 41% in Q2 2026, buying an estimated $33.1M and bringing the position to 4,141,636 shares worth $112M. The position accounts for ﹤0.01% of the portfolio, ranked #1421.

State Street first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $116M in Q4 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • State Street held 4,141,636 shares of Mineralys Therapeutics worth $112M as of Q2 2026.
  • State Street bought 1,205,696 Mineralys Therapeutics shares in Q2 2026, an estimated $33.1M.
  • Mineralys Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1421 holding.
  • State Street first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • State Street's Mineralys Therapeutics position peaked at $116M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.